Uncharted territory my friend. If DC VAX L does what we longs believe, and have good reason to do so, and is not a change in just degree but in kind in not only treating GBM, one of the biggest challenges in oncology, but has potential for treating a broad spectrum of solid tumour cancers either as a mono therapy or in combination with other drugs, i doubt that even if the current pps were a buck today that a BO would occur at $2 bucks. Perhaps as another poster has speculated, the company's valuation in that case might start at $50B.
In a conversation with Les, admittedly a number of years ago, we talked about company value and at what price would management entertain a BO. He said then, when admittedly there were less outstanding shares, that he would not be interested in $50/share when I threw out that number. The point is that NWBO management appears to know what they have and their valuations may be currently far apart from those of interested suitors.
If the trial is successful, patient demand will go through the roof. If you have any experience with GBM, you will know that patients are desperate and are willing to grab onto anything that would spare them the ravages of the disease itself and the current SOC. I know desperation. My wife died of GBM and it was horrible. We were desperate. BP understands this. Desperate demand is there. Question is: what is TLD and if results are positive, what is the valuation in a sea changing paradigm with desperation demand? It certainly ain't anywhere near below a billion. JMHO.
